261 related articles for article (PubMed ID: 31682973)
21. In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants.
Jacqueroux E; Mercier C; Margelidon-Cozzolino V; Hodin S; Bertoletti L; Delavenne X
Fundam Clin Pharmacol; 2020 Feb; 34(1):109-119. PubMed ID: 31411766
[TBL] [Abstract][Full Text] [Related]
22. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
[TBL] [Abstract][Full Text] [Related]
23. Is aspirin a substrate of MDR1/P-glycoprotein?
Singh R; Naik T; Nigam A; Chatterjee S; Rajanna P; Shen H; Iyer R
Xenobiotica; 2020 Oct; 50(10):1258-1264. PubMed ID: 32302241
[TBL] [Abstract][Full Text] [Related]
24. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
[TBL] [Abstract][Full Text] [Related]
25. Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity.
Tu M; Li L; Lei H; Ma Z; Chen Z; Sun S; Xu S; Zhou H; Zeng S; Jiang H
Toxicology; 2014 Aug; 322():34-42. PubMed ID: 24799337
[TBL] [Abstract][Full Text] [Related]
26. Suppression of Canine ATP Binding Cassette ABCB1 in Madin-Darby Canine Kidney Type II Cells Unmasks Human ABCG2-Mediated Efflux of Olaparib.
Song YK; Park JE; Oh Y; Hyung S; Jeong YS; Kim MS; Lee W; Chung SJ
J Pharmacol Exp Ther; 2019 Jan; 368(1):79-87. PubMed ID: 30396915
[TBL] [Abstract][Full Text] [Related]
27. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
D'Cunha R; Bae S; Murry DJ; An G
Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Drug Transport in MDCKII-Wild Type, MDCKII-MDR1, MDCKII-BCRP and Caco-2 Cell Lines.
Mukkavilli R; Jadhav G; Vangala S
Curr Pharm Biotechnol; 2017; 18(14):1151-1158. PubMed ID: 29521222
[TBL] [Abstract][Full Text] [Related]
29. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
30. Estimation of Fetal-to-Maternal Unbound Steady-State Plasma Concentration Ratio of P-Glycoprotein and/or Breast Cancer Resistance Protein Substrate Drugs Using a Maternal-Fetal Physiologically Based Pharmacokinetic Model.
Peng J; Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):613-623. PubMed ID: 35149540
[TBL] [Abstract][Full Text] [Related]
31. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
[TBL] [Abstract][Full Text] [Related]
32. Successful Prediction of Fetal Exposure to Dual BCRP/P-gp Drug Substrates Using the Efflux Ratio-Relative Expression Factor Approach and PBPK M&S.
Balhara A; Yin M; Unadkat JD
Clin Pharmacol Ther; 2024 May; 115(5):1044-1053. PubMed ID: 38124355
[TBL] [Abstract][Full Text] [Related]
33. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the role and quantitative impact of breast cancer resistance protein on drug distribution into brain and CSF in rats.
Katagiri Y; Kawaguchi H; Umemura K; Tadano J; Miyawaki I; Takano M
Drug Metab Pharmacokinet; 2022 Feb; 42():100430. PubMed ID: 34896751
[TBL] [Abstract][Full Text] [Related]
35. Tetrahydrocannabinol and Its Major Metabolites Are Not (or Are Poor) Substrates or Inhibitors of Human P-Glycoprotein [ATP-Binding Cassette (ABC) B1] and Breast Cancer Resistance Protein (ABCG2).
Chen X; Unadkat JD; Mao Q
Drug Metab Dispos; 2021 Oct; 49(10):910-918. PubMed ID: 34326138
[TBL] [Abstract][Full Text] [Related]
36. Successful Prediction of Human Fetal Exposure to P-Glycoprotein Substrate Drugs Using the Proteomics-Informed Relative Expression Factor Approach and PBPK Modeling and Simulation.
Anoshchenko O; Storelli F; Unadkat JD
Drug Metab Dispos; 2021 Oct; 49(10):919-928. PubMed ID: 34426410
[TBL] [Abstract][Full Text] [Related]
37. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach.
Storelli F; Anoshchenko O; Unadkat JD
Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056
[TBL] [Abstract][Full Text] [Related]
38. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
Zhang Y; Huang J; Liu Y; Guo T; Wang L
Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
[TBL] [Abstract][Full Text] [Related]
39. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
[TBL] [Abstract][Full Text] [Related]
40. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]